28657-39-8

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-4-methyl-6-phenylpyridazine is used as a key intermediate in the synthesis of various pharmaceuticals for its potential biological activities. It serves as a valuable building block in the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
3-Chloro-4-methyl-6-phenylpyridazine is used as a precursor in the synthesis of agrochemicals, contributing to the development of novel pesticides and other agrochemical products with enhanced efficacy and selectivity.
Used in Medicinal Chemistry Research:
3-Chloro-4-methyl-6-phenylpyridazine is used as a research compound in medicinal chemistry to explore its potential as an antitumor agent and a potential inhibitor of certain enzymes. Its unique molecular structure and biological activities make it a promising candidate for further investigation and development in the field of drug discovery.

InChI:InChI=1/C11H9ClN2/c1-8-7-10(13-14-11(8)12)9-5-3-2-4-6-9/h2-7H,1H3

Upstream product

• 75-91-2 tert.-butylhydroperoxide 
• 20375-65-9 3-chloro-6-phenylpyradazine 
• 75-07-0 acetaldehyde 
• 13300-09-9 4-methyl-6-phenylpyridazin-3(2H)-one 
• 19064-64-3 3,6-dichloro-4-methylpyridazine 
• 98-80-6 phenylboronic acid 
• 4578-42-1 3-methoxy-6-phenylpyridazine 
• 1771-65-9 2-methyl-4-oxo-4-phenylbutanoic acid 
• 52239-91-5 4-methyl-6-phenyl-4,5-dihydropyridazin-3(2H)-one 
• 10025-87-3 trichlorophosphate 
• 10330-57-1 3-methoxy-4-methyl-6-phenylpyridazine 

Downstream Products

• 32723-45-8 4-methyl-6-phenylpyridazine 
• 118269-78-6 (4-Methyl-6-phenyl-pyridazin-3-yl)-(2-pyrrolidin-1-yl-ethyl)-amine; hydrochloride 
• 118269-79-7 (4-Methyl-6-phenyl-pyridazin-3-yl)-(2-piperidin-1-yl-ethyl)-amine; hydrochloride 
• 81819-94-5 (4-Methyl-6-phenyl-pyridazin-3-yl)-(6-phenyl-pyridazin-3-yl)-amine 
• 118269-71-9 (4-Methyl-6-phenyl-pyridazin-3-yl)-(2-morpholin-4-yl-propyl)-amine; hydrochloride 
• 81820-03-3 10-(4-Methyl-6-phenyl-pyridazin-3-yl)-10H-phenothiazine 
• 81819-99-0 10-(4-Methyl-6-phenyl-pyridazin-3-yl)-10H-phenothiazine 5-oxide 
• 118269-77-5 N'-(4-Methyl-6-phenyl-pyridazin-3-yl)-N,N-dipropyl-ethane-1,2-diamine; compound with oxalic acid 
• 60855-73-4 3-benzoylhydrazino-4-methyl-6-phenylpyridazine 
• 85714-56-3 3-[(Aminoethyl)amino]-4-methyl-6-phenylpyridazine 
• 118269-74-2 N,N-Dimethyl-N'-(4-methyl-6-phenyl-pyridazin-3-yl)-ethane-1,2-diamine; hydrochloride 
• 118269-75-3 N,N-Diethyl-N'-(4-methyl-6-phenyl-pyridazin-3-yl)-ethane-1,2-diamine; compound with oxalic acid 
• 81819-96-7 3-phenylhydrazino-4-methyl-6-phenylpyridazine 
• 118269-72-0 [2-(3-Methyl-morpholin-4-yl)-ethyl]-(4-methyl-6-phenyl-pyridazin-3-yl)-amine; hydrochloride 

Relevant academic research and scientific papers

A new two-step procedure for functionalized-3(2H)-pyridazinones through homolytic substitution of 3-chloropyridazines

The homolytic substitution of protonated 3-chloro-6-methylpyridazine 1a, followed by hydrolysis with AcOH affords 4- or 4,5-functionalized pyridazinones 3a-c. Less reactivity is found for 3-chloro-6-phenylpyridazine 1b. Hypotheses about these different behaviour patterns are proposed and discussed.

Pyridazine N-Oxides as Precursors of Metallocarbenes: Rhodium-Catalyzed Transannulation with Pyrroles

Pyridazine N-oxides are used for the first time as precursors of metallocarbenes. These nitrogen-rich heterocycles led to the discovery of a novel acceptor and donor-acceptor enalcarbenoids. The synthetic utility of these metallocarbenes was demonstrated in the rhodium-catalyzed denitrogenative transannulation of pyridazine N-oxides with pyrroles to the valuable alkyl, 7-aryl, and 7-styryl indoles. The transannulation strategy was applied to the synthesis of a potent anticancer agent.

FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS

The invention relates to chemical compounds, compositions and methods of making and using the same. In particular, the invention provides selected pyridazine compounds of the formula I are independently hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, sulfate, sulfenyl, sulfinyl, sulfonyl, sulfonate, sulfoxide, silyl, silyloxy, silylalkyl, silylthio, ═O, ═S, phosphonate, ureido, carboxyl, carbonyl, carbamoyl, or carboxamide; and X is optionally substituted pyrimidinyl or pyridazinyl, an isomer, a pharmaceutically acceptable salt, or derivative thereof. The invention additional relates to compositions comprising the compounds, and methods of using the compounds and compositions for modulation of cellular pathways, for treatment or prevention of inflammatory diseases, for research, drug screening, and therapeutic applications.

FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits

We report the development of a novel, aqueous-soluble, safe, small molecule, experimental therapeutic that suppresses injury-induced, proinflammatory cytokine increases in the brain, with resultant attenuation of synaptic protein biomarker loss and improvement in hippocampus-dependent behavioral deficits. A GMP production scheme for the active pharmaceutical ingredient, compound 17, is presented. The development and large-scale availability of this novel compound allow exploration of new, potentially disease-modifying, therapeutic approaches to CNS disorders.

COMPOSITIONS AND TREATMENTS FOR DEMYELINATING DISEASES AND PAIN DISORDERS

The invention relates to compositions and methods for treating patients with Demyelinating Diseases and Conditions including Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compositions and methods may also be used for Stroke Rehabilitation and the treatment of pain disorders including Neuropathic Pain and Chemokine-Induced Pain. The compositions comprise one or more pyridazine compounds having a pyridazinyl radical pendant with an aryl or substituted aryl, a heteroaryl or substituted heteroaryl.

SALTS OF PYRIDAZINE COMPOUNDS

The invention relates to stable and substantially purified synthetic pharmaceutically acceptable acid addition salts of pyridazine compounds of the formula I wherein R10 is hydrogen, hydroxyl, alkyl, alkoxy, alkenyl, alkynyl, alkylene, aryl, heteroaryl, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, =0, =S, carboxyl, carbonyl, carbamoyl, carboxamide, or phosphonate, and R11 is alkyl, alkoxy, alkenyl, alkynyl, alkylene, alkenylene, alkenyloxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, =0, =S, phosphonate, carboxyl, carbonyl, carbamoyl, carboxamide, or ureido. The invention also relates to formulations, dosage forms and compositions comprising the salts, and methods of using the salts, formulations, dosage forms and compositions.

COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS

The invention relates to compositions, conjugates and methods comprising pyridazine compounds and cholinesterase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND SECRETASES

The invention relates to compositions, conjugates and methods comprising pyridazine compounds and secretase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

Ortho-Directed Metalation of 3-Heterosubstituted 4-Methyl-6-phenylpyridazines

Side-chain metalation of 4-methyl-6-phenylpyridazines (2-4) with lithium diisopropylamide or 2,2,6,6-tetramethylpiperidide and subsequent alkylation with various electrophiles have been investigated.Depending on the substituent attached at the 3-position (Cl, OMe or NHCOtBu), the prepatration of the alkylated pyridazines was more or less efficient.